Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease‐modifying antirheumatic drugs (DMARDs). METHODS: In a...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413813/
https://www.ncbi.nlm.nih.gov/pubmed/27565000
http://dx.doi.org/10.1002/acr.23004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413813/
https://www.ncbi.nlm.nih.gov/pubmed/27565000
http://dx.doi.org/10.1002/acr.23004

Ejemplares similares